Clinical trial
Maximal Dose of Angiotensin Converting Enzyme (ACE) Inhibitor for Treatment of…
NCT00118976 · Steno Diabetes Center Copenhagen, Other · Completed
Key facts
| NCT number | NCT00118976 |
|---|---|
| Title | Maximal Dose of Angiotensin Converting Enzyme (ACE) Inhibitor for Treatment of Diabetic Kidney Disease |
| Official title | Optimal Dose of ACE Inhibitor for Treatment of Diabetic Nephropathy in Type 1 Diabetic Patients With Hypertension and Diabetic Nephropathy |
| Lead sponsor | Steno Diabetes Center Copenhagen, Other |
| Status | Completed |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type I, Diabetic Nephropathy |
| Intervention type | Drug |
| Interventions | Lisinopril |
| Enrollment | 60 |
| Start date | Mar 1, 2005 |
| Completion | Sep 1, 2006 |
| First posted | Jul 12, 2005 |
| Last update posted | Nov 23, 2006 |
| Countries | Denmark |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: